Dr. Varas focuses on the economic analysis of antitrust and other competition issues. He has conducted economic studies in the healthcare, life science, telecommunication, and retail industries.
Washington, DC
Pablo Varas focuses on the economic analysis of antitrust and other competition issues. He has conducted economic studies in the healthcare, life sciences, telecommunication, and retail industries. His topics of interest include antitrust, damages, and fair market value.
Dr. Varas is fluent in English and Spanish.
Secretariat Experts Contribute to “2024 Annual Review of Antitrust Law Developments”
Secretariat team members Stuart Gurrea, Jéssica Dutra, Wei Tan, Pablo Varas, and Noah Case have contributed to “Chapter I — Restraints of Trade” in the recently published “2024 Annual Review of Antitrust Law Developments” from the ABA Antitrust Law Section. Michael Koenig contributed to “Chapter VIII — Civil Government Enforcement”.
2024 ABA Antitrust Spring Meeting Session Summary: New Frontiers in Market Definition
Pablo Varas authored an article summarizing the 2024 ABA Antitrust Spring Meeting session on new frontiers in market definition. The panelists discussed recent healthcare merger enforcement actions and how companies are seeking to overcome those challenges. The panel discussed the role of market definition as a legal and economic tool in merger reviews and litigations and new tools and approaches to define markets in complex matters.
2024 ABA Antitrust Spring Meeting Session Summary: Attacking and Defending Healthcare Mergers
Pablo Varas authored an article summarizing the 2024 ABA Antitrust Spring Meeting session on healthcare mergers. The panelists discussed recent healthcare merger enforcement actions and how companies are seeking to overcome those challenges. The article highlights key lessons from recent healthcare mergers, in particular the IQVIA-Propel, Amgen-Horizon, and Illumina-Grail mergers. It also gives an outline of recent enforcement actions in hospital mergers and some key topics that appear to interest enforcers when reviewing proposed mergers.